Health-related quality of life in cardiac patients with dyslipidemia and hypertension

Quality of Life Research

Volumn 13, Issue 4, 2004, Pages 793-804

  Lalonde, Lyne ^a,b,i   O'Connor, Annette ^c   Joseph, Lawrence ^d,e,f   Grover, Steven A ^d,f,g   Cassidy, L E ^h   Green, L ^h   Larochelle, D ^h   Motchula, R ^h   McCans, J ^h   McLeod, P J ^h   Repa Fortier, R ^h   Stewart, J A ^h   Blank, D W ^h   Charbonneau, F ^h   Gilfix, B M ^h   Sami, M ^h   Sherman, M H ^h   Smilovitch, M ^h  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b Research Team in Primary Care   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d MONTREAL GENERAL HOSPITAL   (Canada)

^e Dept of Mathematics and Statistics ^*

^f MCGILL UNIVERSITY   (Canada)

^g Ctr Anal of Cost Effective Care   (Canada)

^h ROYAL VICTORIA HOSPITAL   (Canada)

ⁱ Equipe Rech Soins Premiere Ligne A   (Canada)

Author keywords

Coronary heart disease prevention; Cross sectional study; Dyslipidemia; Health related quality of life; Health status; Hypertension; Preference based measures

Indexed keywords

ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DYSLIPIDEMIA; EMOTION; FEMALE; HEALTH STATUS; HEALTH SURVEY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; OUTCOMES RESEARCH; PERCEPTION; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; ROLE PLAYING; SOCIAL STATUS; STATISTICAL SIGNIFICANCE;

ADULT; AGED; ANGINA PECTORIS; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH STATUS; HOSPITALS, UNIVERSITY; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PSYCHOMETRICS; QUALITY OF LIFE; QUEBEC; SICKNESS IMPACT PROFILE;

EID: 11144355158     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:QURE.0000021695.26201.a0     Document Type: Article

References (45)

1. Monk M. Blood pressure awareness and psychological well-being in the health and nutrition examination survey. Clin Invest Med 1981; 4(3/4): 183-189.
2. Bloom JR, Monterossa S. Hypertension labeling and sense of well-being. Am J Public Health 1981; 71: 1228-1232.
3. Soghikian K, Fallick-Hunkeler EM, Ury HK, Fisher AA. The effect of high blood pressure awareness and treatment on emotional well-being. Clin Invest Med 1981; 4(3/4): 191-196.
4. Milne BJ, Logan AG, Flanagan P. Alterations in health perception and life-style in treated hypertensives. J Chron Dis 1985; 38(1): 37-45.
5. Stewart AL, Greenfield S, Hays RD, et al. Functional status and well-being of patients with chronic conditions: Results from the Medical Outcomes Study. JAMA 1989; 262: 907-913.
6. Bardage C, Isacson D. Hypertension and health-related quality of life: An epidemiological study in Sweden. J Clin Epidemiol 2001; 54: 172-181.
7. Lawrence WF, Fryback DG, Martin PA, Klein R, Klein BEK. Health status and hypertension: A population-based study. J Clin Epidemiol 1996; 49(11): 1239-1245.
8. Polk BF, Harlan LC, Cooper SP, et al. Disability days associated with detection and treatment in a hypertension control program. Am J Epidemiol 1984; 119(1): 44-53.
9. Haynes RB, Sackett DL, Taylor DW, Gibson ES, Johnson AL. Increased absenteeism from work after detection and labeling of hypertensive patients. N Engl J Med 1978; 299: 741-744.
10. Charlson ME, Alderman M, Melcher L. Absenteeism and labelling in hypertensive subjects. Prevention of an adverse impact in those at high risk. Am J Med 1982; 73: 165-170.
11. Alderman MH, Charlson ME, Melcher LA. Labelling and absenteeism: The Massachusetts mutual experience. Clin Invest Med 1981; 4(3/4): 165-171.
12. Wassertheil-Smoller S, Blaufox MD, Oberman A, et al. Effect of antihypertensives on sexual function and quality of life: The TAIM Study. Ann Int Med 1991; 114(8): 613-620.
13. The Treatment of Mild Hypertension Research Group. The treatment of mild hypertension study. A randomized, placebo-controlled trial of a nutritional-hygienic regimen along with various drug monotherapies. Arch Int Med 1991; 151(7): 1413-1423.
14. Jachuck SJ, Brierley H, Jachuck S, Willcox PM. The effect of hypotensive drugs on the quality of life. J R Coll Gen Pract 1982; 32: 103-105.
15. Croog SH, Levine S, Testa MA, et al. The effects of anti-hypertensive therapy on the quality of life. N Engl J Med 1986; 314: 1657-1664.
16. Havas S, Reisman J, Hsu L, Koumjian L. Does cholesterol screening result in negative labeling effects? Results of the Massachusetts Model Systems for Blood Cholesterol Screening Project. Arch Intern Med 1991; 151: 113-119.
17. Forrow L, Galkins D, Allshouse K, Delbanco T. Effects of cholesterol screening on health perceptions. Clin Res 1989; 37: 818A.
18. Irvine MJ, Logan AG. Is knowing your cholesterol number harmful? J Clin Epidemiol 1984; 47(2): 131-145.
19. Lalonde L, Clarke AE, Joseph L, Mackenzie T, Grover SA, The Canadian Collaborative Cardiac Assessment Group. Health-related quality of life in coronary heart disease prevention and treatment. J Clin Epidemiol 2001; 54: 1011-1018.
20. Lawrence WF, Fryback DG, Martin PA, et al. Cholesterol and health status in the Beaver Dam Health Outcomes Study (abstract). Med Decis Making 1994; 14: 436.
21. Lalonde L, Clarke AE, Joseph L, Grover SA, The Canadian Collaborative Cardiac Assessment Group. Conventional and chained standard gamble in the assessment of coronary heart disease prevention and treatment. Med Decis Making 1999; 19: 149-156.
22. Lalonde L, Clarke AE, Joseph L, Mackenzie T, Grover SA, The Canadian Collaborative Cardiac Assessment Group. Comparing the psychometric properties of preference-based and nonpreference-based health-related quality of life in coronary heart disease. Qual Life Res 1999; 8: 399-409.
23. Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam health outcomes study: Initial catalog of health-state quality factors. Med Decis Making 1993; 13: 89-102.
24. Goldman L, Cook EF, Mitchell N, Flatley M, Sherman H, Cohn PF. Pitfalls in the serial assessment of cardiac functional status. How a reduction in "ordinary" activity may reduce the apparent degree of cardiac compromise and give a misleading impression of improvement. J Chron Dis 1982; 35: 763-771.
25. Goldman L, Hashimoto B, Cook F, Loscalzo A. Comparative reproducibility and validity of systems for assessing cardiovascular functional class: Advantages of a new specific activity scale. Circulation 1981; 64: 1227-1234.
26. Ware JE, Gandek B, for the IQOLA Project. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol 1998; 51(11): 903-912.
27. Ware JE, Kosinski M, Keller SD. SF-36 Physical and Mental Health Summary Scales: A User's Manual. Boston, MA: The Health Institude, 1994.
28. Furlong W, Feeny D, Torrance G, Barr R, Horsman J. Guide to Design and Development of Health-State Utility Instrumentation. Hamilton, Canada: McMaster University University, 1990.
29. Morss SE, Lenert LA, Faustmann WO. The Side Effects of Anti-Psychotic Drugs and Patients' Quality of Life: Patient Education and Preference Assessment with Computers and Multimedia. Proceeding of the 17th annual Symposium on Computer Applications in Medical Care. New York: McGraw Hill, 1993: 17-22.
30. Fortin PR, Clarke AE, Joseph L, et al. Outcomes of total hip and knee replacement. Arthritis Rheum 1999; 42(8): 1722-1728.
31. Cleeman JI, Lenfant C. The National Cholesterol Education Program. Progress and prospects. JAMA 1998; 280(24): 2099-2104.
32. Frohlich J, Fodor G, McPherson R, Genest J, Langner N, for the Dyslipidemia Working Group of Health Canada. Rational for and outline of the recommendations of the Working Group on Hypercholesterolemia and Other Dyslipidemias: Interim report. Can J Cardiol 1998; 14(Suppl A): 17A-21A.
33. Pearson TA, McBride PE, Miller NH, Smith SC. Task Force 8: Organization of preventive cardiology service. J Am Coll Cardiol 1996; 27: 1039-1047.
34. The EUROASPIRE Study Group. A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. Eur Heart J 1997; 18: 1569-1582.
35. Keech A, on behalf of the Asian-Pacific CHD Risk Factor Collaborative Group. Risk factor management in CHD patients in Asia: Current status. Atherosclerosis 1998; 136(Suppl): S31.
36. Bowker TJ, Clayton TC, Ingham J, et al. A British Cardiac Society survey of the potential for secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). Heart 1996; 75: 334-342.
37. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
38. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravasatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
39. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and broad range of initial cholesterol levels. N Engl J Med 1998; 339(19): 1349-1357.
40. Franklin BA, Kalm JK. Delayed progression or regression of coronary atherosclerosis with intensive risk factor modification. Effects of Diet, Drugs, and Exercise. Sports Med 1996; 22(5): 301-319.
41. Pedersen TR, Kjekshus J, Berg K, et al. Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. Circulation 1996; 93: 1796-1802.
42. Selwyn AP, Kinlay S, Libby P, Ganz P. Atherogenic lipids, vascular dysfunction, and clinical signs of ischemic heart disease. Circulation 1997; 95: 5-7.
43. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995; 332: 488-493.
44. Leung WH, Lau CP, Wong CK. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemic patients. Lancet 1993; 341: 1496-1500.
45. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332: 481-487.